As we celebrate the success of Empact Ventures’ 2021 Super Connect for Good competition in partnership with Hays, we catch up with Maciej’ Matt’ Szurek, Chief Executive Officer at RemmedVR.
Hays and Empact Ventures’ 2021 Super Connect for Good competition was successful. The virtual final, which took place in November, saw the regional winners go head-to-head by pitching live for the Super Connect for Good 2021 Overall Champion. Maciej ‘Matt’ Szurek, Chief Executive Officer of RemmedVR, was the Central and Eastern Europe regional winner.
Growing telemedicine in neurology and eyecare
RemmedVR is a telemedical platform for diagnostic and rehabilitation services within neurology and eye care. As a deep tech company, they have developed their own software and hardware while also going through medical certification and clinical trials. Entering the next step, Szurek explained that “we are approaching the point where we will be trying to get some of our services reimbursed in the United States.”
At this stage, RemmedVR is placing two-thirds of their raised money to their research and development (R&D) department. “With just over 50 people, we have a lead in fast in engineers, software developers, scientists, and medical doctors to deliver the product that consists of three major elements: software, hardware, and methodology,” said Szurek. The RemmedVR team has created this technology from scratch in-house, which allows them to influence or change any of the critical elements of their solution based on feedback from clients and users.
Many startups follow the minimum viable product route, which will cost less, lower risk, and reduce time. However, RemmedVR “decided to go full blast from the beginning, which included some heavy lifting and cost us a lot of stress and struggle, but after the five years, it started to pay off,” added Szurek.
“Due to our approach, of having the three components in house methodology, software, data science, optics, hardware, we were able to quickly move from rehabilitation to diagnostics, explained Szurek. The main competitive advantage RemmedVR has is that their business model sells its solution as a service with the software and hardware being provided as a monthly subscription. Therefore, clients and their patients don’t have to purchase the equipment, provide a down payment or entry fee. “With clients getting more set-ups
Another point of differentiation is that “the whole system was designed to be fully functional, remotely at patient’s home with the full supervision, remote supervision of the therapists,” explained Szurek. The system was developed to be remote and has since been adapted for clinical services by providing additional components to serve the touch screen with a control panel that manages all the patients and therapists.
Success for RemmedVR
The last two years have been very successful for RemmedVR as there has been an increase within the telemedicine industry during Covid-19. In addition, there have been many governmental incentives and new regulations that have sped up the adoption of telemedical solutions. “For our clients, the lockdowns helped them sell their services to their patients due to them being able to conduct their therapeutic procedures remotely,” said Szurek.
- The top MedTech innovations of 2021
- 5G: Pushing the world forward through emerging technologies
- The rise of lights-out automation in medtech
- Medical innovation in the COVID era
At the end of January, RemmedVR was invited to participate at the SPIE Photonics conference in San Francisco. This is a prestigious conference for premier lasers, biomedical optics, and optoelectronics producers. Szurek explained, “their participation is mostly for our R&D team to present our camera-free eye-tracking solution that we have patented. At the conference, RemmedVR will meet with partners interested in its eye-tracking, not even particularly for medical purposes, but for XR arc application, so VR, AR, mixed reality devices.”